AR046313A1 - Compuesto de 2-cianopirrolidincarboxamida, un metodo para su obtencion y su empleo en composiciones farmaceuticas y en medicamentos con actividad inhibitoria de la dipeptidil peptidasa-iv (dpp-iv). - Google Patents

Compuesto de 2-cianopirrolidincarboxamida, un metodo para su obtencion y su empleo en composiciones farmaceuticas y en medicamentos con actividad inhibitoria de la dipeptidil peptidasa-iv (dpp-iv).

Info

Publication number
AR046313A1
AR046313A1 ARP040104001A ARP040104001A AR046313A1 AR 046313 A1 AR046313 A1 AR 046313A1 AR P040104001 A ARP040104001 A AR P040104001A AR P040104001 A ARP040104001 A AR P040104001A AR 046313 A1 AR046313 A1 AR 046313A1
Authority
AR
Argentina
Prior art keywords
lower alkyl
substituent
independently
compound
dpp
Prior art date
Application number
ARP040104001A
Other languages
English (en)
Original Assignee
Fujisawa Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2003906010A external-priority patent/AU2003906010A0/en
Application filed by Fujisawa Pharmaceutical Co filed Critical Fujisawa Pharmaceutical Co
Publication of AR046313A1 publication Critical patent/AR046313A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems

Abstract

El presente se refiere al compuesto que tiene actividad inhibidora de la actividad de DPP-IV. Por lo tanto son útiles en el tratamiento de afecciones mediadas por DPP-IV, tales como NIDDM. Reivindicación 1: Un compuesto de la fórmula (1) o su sal aceptable desde el punto de vista farmacéutico, caracterizado porque X1 y X2 son cada uno en forma independiente alquileno inferior; X3 es =CH2, =CHF o =CF2;R1 es un sustituyente; R2 y R3 son, en forma independiente, H o alquilo inferior; n es 0, 1, 2, 3 ó 4. Reivindicación 25: Un método para producir el compuesto (1) caracterizado porque desproteger el compuesto (2), en el cual X1 y X2 son, cada uno en forma independiente, alquileno inferior; X3 es =CH2, =CHF o =CF2; R1 es un sustituyente; R2 y R3 son, en forma independiente, H o alquilo inferior; n es 0, 1, 2, 3 ó 4; R1' es R1 protegido para no inhibir esta reacción, si es necesario; Pro es el grupo protector del grupo amino. Reivindicación 26: Un compuesto de fórmula (3) o su sal aceptable desde el punto de vista farmacéutico; caracterizado porque: Y1 es -O-, -S- o =NR16; Y2 es =CHF o =CF2; R11 es alquilo inferior o alquilo inferior sustituido por hidroxi; R12, R13, R14 y R15 son, en forma independiente, H, alquilo inferior o R13 y R14 pueden estar conectados para formar un alquileno inferior; R16 es alquilo inferior, heteroarilo (sustituido en forma opcional por el sustituyente (i)) o [alquil inferior de cadena recta]sulfonilo; el sustituyente (i) se selecciona del grupo formado por alquilo inferior, alcoxi inferior, amino, carboxi, hidroxi, ciano y halógeno. Reivindicación 35: Un compuesto de fórmula (4) o su sal aceptable desde el punto de vista farmacéutico, caracterizado porque: Z1 es -O-, -S- o =NR24; Z2 es =CH2, =CHF = =CF2; R21 es H, alquilo inferior o alquilo inferior sustituido por hidroxi; R22 y R23 son, en forma independiente, H, alquilo inferior; R24 es alquilo inferior, heteroarilo (sustituido en forma opcional por el sustituyente (ii)) o [alquil inferior de cadena recta]sulfonilo; el anillo bencénico puede estar sustituido en forma opcional por el sustituyente (ii); el sustituyente (ii) se selecciona del grupo formado por alquilo inferior, alcoxi inferior, amino, carboxi, hidroxi, ciano y halógeno.
ARP040104001A 2003-10-31 2004-10-29 Compuesto de 2-cianopirrolidincarboxamida, un metodo para su obtencion y su empleo en composiciones farmaceuticas y en medicamentos con actividad inhibitoria de la dipeptidil peptidasa-iv (dpp-iv). AR046313A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2003906010A AU2003906010A0 (en) 2003-10-31 DPP-IV Inhibitor
AU2004900961A AU2004900961A0 (en) 2004-02-25 DPP-IV inhibitor

Publications (1)

Publication Number Publication Date
AR046313A1 true AR046313A1 (es) 2005-11-30

Family

ID=34553068

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040104001A AR046313A1 (es) 2003-10-31 2004-10-29 Compuesto de 2-cianopirrolidincarboxamida, un metodo para su obtencion y su empleo en composiciones farmaceuticas y en medicamentos con actividad inhibitoria de la dipeptidil peptidasa-iv (dpp-iv).

Country Status (17)

Country Link
US (1) US7186731B2 (es)
EP (1) EP1737863B1 (es)
JP (1) JP4636021B2 (es)
KR (1) KR20060100390A (es)
AR (1) AR046313A1 (es)
AT (1) ATE419250T1 (es)
BR (1) BRPI0415587A (es)
CA (1) CA2543533A1 (es)
CO (1) CO5690603A2 (es)
DE (1) DE602004018837D1 (es)
ES (1) ES2320557T3 (es)
IL (1) IL175214A0 (es)
MX (1) MXPA06004797A (es)
NO (1) NO20062517L (es)
RU (1) RU2006118789A (es)
TW (1) TW200528440A (es)
WO (1) WO2005042533A2 (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE437870T1 (de) 2004-05-12 2009-08-15 Pfizer Prod Inc Prolinderivate und deren verwendung als dipeptidylpeptidase-iv-inhibitoren
US20060199853A1 (en) * 2005-02-18 2006-09-07 Charles Mioskowski Analogs of 4-hydroxyisoleucine and uses thereof
WO2006131836A2 (en) * 2005-03-22 2006-12-14 Innodia Inc. Compounds and compositions for use in the prevention and treatment of obesity and related syndromes
US7553861B2 (en) 2005-04-22 2009-06-30 Alantos Pharmaceuticals Holding, Inc. Dipeptidyl peptidase-IV inhibitors
CN101232873A (zh) * 2005-08-11 2008-07-30 霍夫曼-拉罗奇有限公司 含有dpp-iv抑制剂的药物组合物
GB0526291D0 (en) 2005-12-23 2006-02-01 Prosidion Ltd Therapeutic method
WO2007107008A1 (en) * 2006-03-22 2007-09-27 Innodia Inc. Compounds and compositions for use in the prevention and treatment of disorders of fat metabolism and obesity
PE20071221A1 (es) 2006-04-11 2007-12-14 Arena Pharm Inc Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
US7727978B2 (en) * 2006-08-24 2010-06-01 Bristol-Myers Squibb Company Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors
GB0713602D0 (en) * 2007-07-12 2007-08-22 Syngenta Participations Ag Chemical compounds
GB2465132B (en) * 2007-09-21 2012-06-06 Lupin Ltd Compounds as dipeptidyl peptidase IV (DPP IV) inhibitors
JP5305704B2 (ja) * 2008-03-24 2013-10-02 富士フイルム株式会社 新規化合物、光重合性組成物、カラーフィルタ用光重合性組成物、カラーフィルタ、及びその製造方法、固体撮像素子、並びに、平版印刷版原版
EP2146210A1 (en) 2008-04-07 2010-01-20 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY
WO2010146597A1 (en) 2009-06-18 2010-12-23 Lupin Limited 2-amino-2- [8-(dimethyl carbamoyl)- 8-aza- bicyclo [3.2.1] oct-3-yl]-exo- ethanoyl derivatives as potent dpp-iv inhibitors
US8999975B2 (en) * 2011-09-19 2015-04-07 Boehringer Ingelheim International Gmbh Substituted N- [1-cyano-2- (phenyl) ethyl] -2-azabicyclo [2.2.1] heptane-3-carboxamide inhibitors of cathepsin C
CA3012242C (en) 2012-12-21 2021-11-02 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
WO2014140091A1 (en) 2013-03-14 2014-09-18 Boehringer Ingelheim International Gmbh Substituted 2-aza-bicyclo[2.2.2]octane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c
NZ710034A (en) 2013-03-14 2020-06-26 Boehringer Ingelheim Int Substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c
JP6411491B2 (ja) 2013-07-12 2018-10-24 ギリアード サイエンシス インコーポレーテッド 多環式カルバモイルピリドン化合物およびｈｉｖ感染症を処置するためのその使用
NO2865735T3 (es) 2013-07-12 2018-07-21
NO2717902T3 (es) 2014-06-20 2018-06-23
TWI744723B (zh) 2014-06-20 2021-11-01 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
JP6529575B2 (ja) 2014-08-01 2019-06-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 置換オキセタンおよびそれらのカテプシンｃの阻害薬としての使用
KR102510588B1 (ko) 2014-09-12 2023-03-17 베링거 인겔하임 인터내셔날 게엠베하 카텝신 c의 스피로사이클릭 억제제
TWI738321B (zh) 2014-12-23 2021-09-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
EA201791982A1 (ru) 2015-03-09 2020-02-17 Интекрин Терапьютикс, Инк. Способы лечения неалкогольной жировой болезни печени и/или липодистрофии
AU2016244035B2 (en) 2015-04-02 2018-11-01 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
CA3058806A1 (en) 2017-04-03 2018-10-11 Coherus Biosciences Inc. Ppar.gamma. agonist for treatment of progressive supranuclear palsy
IT201700059292A1 (it) * 2017-05-31 2018-12-01 Univ Pisa Derivati 1,3-diaza-4-ossa-[3.3.1]-biciclici, loro preparazione e uso come medicinale, in particolare per il trattamento del diabete
US20210198283A1 (en) 2018-08-08 2021-07-01 Sumitomo Dainippon Pharma Co., Ltd. Optically active bridged piperidine derivative
CN112585140B (zh) 2018-08-27 2023-07-04 住友制药株式会社 光学活性氮杂双环衍生物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003057144A2 (en) * 2001-12-26 2003-07-17 Guilford Pharmaceuticals Change inhibitors of dipeptidyl peptidase iv
TW200401635A (en) * 2002-07-23 2004-02-01 Yamanouchi Pharma Co Ltd 2-Cyano-4-fluoropyrrolidine derivative or salt thereof

Also Published As

Publication number Publication date
CO5690603A2 (es) 2006-10-31
US20050137224A1 (en) 2005-06-23
BRPI0415587A (pt) 2007-01-02
EP1737863A2 (en) 2007-01-03
ES2320557T3 (es) 2009-05-25
DE602004018837D1 (de) 2009-02-12
NO20062517L (no) 2006-07-21
US7186731B2 (en) 2007-03-06
MXPA06004797A (es) 2006-07-03
WO2005042533A3 (en) 2005-09-01
CA2543533A1 (en) 2005-05-12
JP4636021B2 (ja) 2011-02-23
IL175214A0 (en) 2006-09-05
KR20060100390A (ko) 2006-09-20
JP2007510619A (ja) 2007-04-26
TW200528440A (en) 2005-09-01
WO2005042533A2 (en) 2005-05-12
EP1737863B1 (en) 2008-12-31
ATE419250T1 (de) 2009-01-15
RU2006118789A (ru) 2007-12-10

Similar Documents

Publication Publication Date Title
AR046313A1 (es) Compuesto de 2-cianopirrolidincarboxamida, un metodo para su obtencion y su empleo en composiciones farmaceuticas y en medicamentos con actividad inhibitoria de la dipeptidil peptidasa-iv (dpp-iv).
PE20110100A1 (es) Procedimiento de preparacion de n-[trans-4-[4-(ciclopropilmetil)-1-piperazinil]ciclohexil]-4-[[(7r)-7-etil-5,6,7,8-tetrahidro-5-metil-8-(1-metiletil)-6-oxo-2-pteridinil]amino]-3-metoxi-benzamida
AR051026A1 (es) Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
AR057023A1 (es) Compuestos heterociclicos con propiedades inhibidoras de hiv-integrasa
ECSP077402A (es) Derivados de 2-amido-4-feniltiazol, su preparación y su aplicación en terapéutica
TW200606151A (en) Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
TW200603799A (en) Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
AR048266A1 (es) Compuesto de benzazepina, composicion farmaceutica que lo comprende y su uso para prepararla
AR053415A1 (es) Inhibidores dipeptidil peptidasa iv, composiciones farmaceuticas que los contienen y procesos para la preparacion de los compuestos y de la composicion
AR067105A1 (es) Moleculas pequenas que contienen boro
MX2007005694A (es) Nuevos derivados de betulina, preparacion y uso de los mismos.
WO2009065919A3 (de) Organische verbindungen
BRPI0518581A2 (pt) compostos de cromanilurÉia que inibem o receptor do subtipo 1 do recepetor vanilàide (vr1) e usos destes
AR060545A1 (es) Compuestos de benzoaxol y benzotiazol 6-0- sustituidos y metodos de inhibicion de la senalizacion de csf-1r. composiciones farmaceuticas
TW200602338A (en) Selected CGRP antagonists, process for preparing them and their use as pharmaceutical compositions
BR0313078A (pt) Composto ou um sal deste farmaceuticamente aceitável, composição farmacêutica, e, uso do composto ou de um sal deste farmaceuticamente aceitável
DE602007012142D1 (en) 3-heteroaryl (amino bzw. amido)-1- (biphenyl bzw. phenylthiazolyl) carbonylpiperdinderivate als orexinrezeptor-inhibitoren
WO2009065920A3 (de) Verbindungen
MX2010003002A (es) Analogos de azacitidina y sus usos.
WO2004096134A3 (en) Substituted 1,4-diazepines and uses thereof
HRP20120310T1 (hr) Derivati benzazepina korisni kao antagonisti vazopresina
WO2005009975A3 (en) Benzimidazole derivatives as mek inhibitors
MX2009003874A (es) Derivados de espiro-oxindol triciclicos y sus usos como agentes terapeuticos.
MY146623A (en) Substituted prolinamides, manufacturing, and the use thereof as medicaments
TW200740806A (en) Bridged N-cyclic sulfonamido inhibitors of gamma secretase

Legal Events

Date Code Title Description
FA Abandonment or withdrawal